November 2, 2017

Poxel Announces Participation at the Jefferies 2017 London Healthcare Conference

LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes, announced today that it will be featured as a presenting company at the Jefferies 2017 London Healthcare Conference.

The Jefferies Conference is being held on November 15-16th at the Waldorf Hilton, Aldwych, London. The Company will present a corporate overview on Wednesday, November 15th at 5:20-5:55 pm GMT in 5 Executive Lounge and will be available to participate in one-on-one meetings with investors. The presentation at the Jefferies conference will be webcast live. To access the webcast, please visit the following link http://wsw.com/webcast/jeff108/poxel.pa. The webcast replay will remain available for 90 days following the live presentation.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes. We have successfully completed our Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., EU and Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com)

View source version on businesswire.com:
http://www.businesswire.com/news/home/20171102006012/en/

Poxel SA
Jonae R. Barnes, +1 617-818-2985
Senior Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
or
Investor relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May, + 49 89 2424 3494 or + 49 175 571 1562
smay@macbiocom.com
or

Investor relations / Media - France
NewCap
Florent Alba/Nicolas Mérigeau, + 33 1 44 71 98 55
poxel@newcap.fr

Source: Poxel SA